Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
10934 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 6003
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| BIIB059 (litifilimab) NCT06044337 · AMETHYST LTE — A Long-Term Extension Study to Learn More About the Safety of Lit… | Lupus | Traitement symptomatique · Thérapie génique | Phase 3 | ENROLLING_BY_INVITATION | In this study, researchers will learn more about a study drug called BIIB0… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| CC-97540 NCT05869955 · A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Seve… | Lupus | Immunomodulation | Phase 1 | ACTIVE_NOT_RECRUITING | The purpose of this study is to establish the tolerability, preliminary ef… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| CC-97540 NCT07015983 · A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, i… | Lupus | Immunomodulation | Phase 2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to establish the tolerability, preliminary ef… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| ECHOS — Engagement in CHildhood-Onset Systemic Lupus NCT05693571 · NCT05693571 | Lupus | Traitement symptomatique | Non applicable | ACTIVE_NOT_RECRUITING | The goal of this observational (Aim 1) and pilot study (Aim 2) is to bette… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservatio… NCT05567198 · NCT05567198 | Lupus | Traitement symptomatique | À vérifier | RECRUITING | Background: Systemic lupus erythematosus (SLE) is a disease that affects f… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| Hydroxychloroquine NCT05799378 · SHIELD — Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | Lupus | Immunomodulation · Traitement symptomatique | Phase 3 | RECRUITING | Women with antibodies to proteins called SSA/Ro and or SSB/La face a 2% ch… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| LUPKYNIS NCT07611214 · PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in… | Lupus | À vérifier | Phase 4 | RECRUITING | The goal of this clinical study is to assess the efficacy and safety of LU… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| Obecabtagene autoleucel (obe-cel) NCT06333483 · CARLYSLE — Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refra… | Lupus | Immunomodulation | Phase 1 | ACTIVE_NOT_RECRUITING | This is a Phase 1 study of obecabtagene autoleucel (obe-cel), autologous T… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| Obinutuzumab NCT05039619 · POSTERITY — A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Ob… | Lupus | À vérifier | Phase 2 | RECRUITING | This phase II, randomized, double-blind, placebo-controlled study is desig… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| P-CD19CD20-ALLO1 Cells NCT06984341 · A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamic… | Lupus | Immunomodulation | Phase 1 | WITHDRAWN | The purpose of this study is to evaluate the safety and tolerability of P-… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:32 | Détail |
| ACG102 Injection NCT07749430 · A Clinical Study of ACG102 Injection in Patients With Refractory Active Systemic… | Lupus | À vérifier | Phase 1 | NOT_YET_RECRUITING | The purpose of this study is to evaluate the safety, tolerability, pharmac… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:31 | Détail |
| BI 3000202 NCT07409181 · A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic… | Lupus | À vérifier | Phase 2 | RECRUITING | This study is open to adults with systemic lupus erythematosus (SLE). The… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:31 | Détail |
| SAR441344 IV NCT05039840 · APATURA — Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Syst… | Lupus | À vérifier | Phase 2 | ACTIVE_NOT_RECRUITING | This is a multinational, randomized, placebo-controlled, parallel treatmen… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:31 | Détail |
| ABBV-319 NCT06977724 · A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effect… | Lupus | Immunomodulation · Traitement symptomatique | Phase 1 | RECRUITING | Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disea… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| Anifrolumab NCT06795893 · The Anifrolumab PRIM Program | Lupus | À vérifier | À vérifier | RECRUITING | This is an observational study, in which the main research question is to… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| Creating Health Course Study for People With Rheumatological Conditio… NCT07180537 · NCT07180537 | Lupus | Traitement symptomatique | Non applicable | RECRUITING | The goal of this project is to critically evaluate the effectiveness of an… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| DZP NCT06617325 · PHOENYCS FLY — A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pego… | Lupus | À vérifier | Phase 3 | RECRUITING | The purpose of this study is to evaluate the ability of dapirolizumab pego… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| ESG206 NCT07760155 · A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibod… | Lupus | À vérifier | Phase 2 | NOT_YET_RECRUITING | This is a multicenter, randomized, double-blind, placebo-controlled Phase… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms NCT07203157 · NCT07203157 | Lupus | Traitement symptomatique | Non applicable | ACTIVE_NOT_RECRUITING | The purpose of this study is to assess the efficacy, feasibility, and acce… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
| HN2301 injection NCT06801119 · SLE,SSc,RA — Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs) | Lupus | À vérifier | Phase 1 | RECRUITING | This is an open lable and single arm study, is designed to evaluate the sa… À vérifier | ClinicalTrials.gov 2026-08-13 14:17:30 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4910
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| A comparative study of the role of crocin and sitagliptin in attenuat… Standard Oral Hypoglycemic Agent · PMID 31394428 | Maladie rénale chronique | Ralentissement de la progression · Immunomodulation | Publication | PubMed | Voir la publication source Type 1 diabetes mellitus (T1DM) describes a complex group of metabolic disorders associated with elevated blood glucose… | Environmental toxicology and pharmacology 2026-11-15 04:38:02 | Source |
| Anti diabetic effect of Achyranthes rubrofusca leaf extracts on allox… Standard Oral Hypoglycemic Agent · PMID 21454169 | Maladie rénale chronique | À vérifier | Publication | PubMed | Voir la publication source The aqueous and ethanolic extracts of Achyranthes rubrofuca leaves (AR) were studied for their hypoglycemic activity. T… | Pakistan journal of pharmaceutical sciences 2026-11-15 04:38:02 | Source |
| Antihyperglycemic and hypolipidemic activities of Setaria italica see… Standard Oral Hypoglycemic Agent · PMID 20869855 | Maladie rénale chronique | À vérifier | Publication | PubMed | Voir la publication source Setaria italica is commonly known as Foxtail millet. In India it is chiefly cultivated in Andhra Pradesh and Tamilnadu.… | Pathophysiology : the official journal of the Internat… 2026-11-15 04:38:02 | Source |
| Enhancing neoadjuvant immunotherapy for locally advanced rectal cance… HJB647 high dose · PMID 42860120 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source Conventional surgery for locally advanced rectal cancer (LARC) faces challenges including difficult sphincter preservat… | Biomaterials 2026-11-15 04:37:50 | Source |
| Oxygen-vacancy-rich LDH sonosensitizers potentiate narrow-spectrum an… HJB647 high dose · PMID 42910182 | Insuffisance cardiaque | Neuroprotection · Immunomodulation · Thérapie génique | Publication | PubMed | Voir la publication source Mixed bacterial infections, including Gram-positive and Gram-negative pathogens, remain a major global health concern.… | Bioactive materials 2026-11-15 04:37:50 | Source |
| Respiratory Support With Nasal High Flow Reduces Opioid Requirements… HJB647 high dose · PMID 42699223 | Insuffisance cardiaque | À vérifier | Publication | PubMed | Voir la publication source Nasal high flow (NHF) improves oxygenation, reduces the work of breathing, and stabilizes ventilation. In endoscopic re… | DEN open 2026-11-15 04:37:50 | Source |
| Feasibility of a Deep-Learning Model for Objective Visualization-Qual… Lithotripsy · PMID 42898633 | Maladie coronarienne | À vérifier | Publication | PubMed | Voir la publication source During peroral cholangioscopy-guided electrohydraulic lithotripsy (EHL), stone fragmentation obscures the visual field… | DEN open 2026-11-15 04:37:45 | Source |
| Impact of calcium burden, lesion preparation, and lithotripsy on sten… Lithotripsy · PMID 42777787 | Maladie coronarienne | À vérifier | Publication | PubMed | Voir la publication source Stent underexpansion in severely calcified coronary lesions increases the risk of target vessel failure. Intravascular… | International journal of cardiology 2026-11-15 04:37:45 | Source |
| Intravascular lithotripsy for calcific stenosis of the abdominal aort… Lithotripsy · PMID 43001236 | Maladie coronarienne | À vérifier | Publication | PubMed | Voir la publication source Takayasu arteritis is a rare large-vessel vasculitis that predominantly affects the aorta and its major branches. Altho… | Journal of vascular surgery cases and innovative techn… 2026-11-15 04:37:45 | Source |
| Placenta-derived mesenchymal stem cells for prenatal myelomeningocele… cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells · PMID 42… | Sclérose en plaques · Sclérose latérale amyotrophique · Sclérose laté… | Thérapie cellulaire | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | Annals of translational medicine 2026-11-15 04:37:41 | Source |
| Synovial Biomarker Modulation and Clinical Response to Umbilical Cord… cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells · PMID 42… | Sclérose en plaques · Sclérose latérale amyotrophique · Sclérose laté… | Immunomodulation · Thérapie cellulaire | Publication | PubMed | Voir la publication source ObjectiveUmbilical cord-derived mesenchymal stromal cells (UC-MSCs) are a promising treatment for knee osteoarthritis (… | Cartilage 2026-11-15 04:37:41 | Source |
| Design, synthesis, and biological evaluation of 1H-1,2,4-triazole-3-c… B007 · PMID 42142713 | Insuffisance cardiaque | À vérifier | Publication | PubMed | Voir la publication source The apelin receptor (AplnR) is a prominent peptide-binding Class A G protein-coupled receptor (GPCR) involved in the re… | Bioorganic & medicinal chemistry letters 2026-11-15 04:37:34 | Source |
| Programmable Nanobody-Targeting Chimeras Enable Intracellular Viral P… B007 · PMID 42467897 | Myasthénie | À vérifier | Publication | PubMed | Voir la publication source Chronic hepatitis B virus (HBV) infection remains a major global health challenge, largely because current antiviral th… | Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026-11-15 04:37:34 | Source |
| Understanding the Selectivity of Selective Oxidation of Propane to Ac… B007 · PMID 41768713 | Myasthénie | À vérifier | Publication | PubMed | Voir la publication source In this work, we have performed a quantum chemical investigation for the selective oxidation of propane toward acrylic… | ACS omega 2026-11-15 04:37:34 | Source |
| Comparative efficacy and acceptability of antidepressants in the long… Milnacipran · PMID 43008763 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Major depressive disorder carries high risks of relapse and chronicity, necessitating treatments that achieve and maint… | The lancet. Psychiatry 2026-11-15 04:37:30 | Source |
| Polysubstance-Induced Vasoplegia Managed with Venoarterial Extracorpo… Milnacipran · PMID 43014364 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source While the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) becomes increasingly commonplace in overdos… | Clinical practice and cases in emergency medicine 2026-11-15 04:37:30 | Source |
| Early Outcome of a Single Peri-Tendinous Hyaluronic Acid Injection fo… Sodium hyaluronate with mannitol (Ostenil Tendon) · PMID 33132010 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source The aim of this study was to evaluate the efficacy and safety of a single, peri-tendinous injection of hyaluronic acid… | Foot (Edinburgh, Scotland) 2026-11-15 04:37:29 | Source |
| Engineered stem cell-derived CD16-enhanced universal NKT cells improv… Tafasitamab and NK cells · PMID 43008138 | Cancer | Immunomodulation · Thérapie cellulaire | Publication | PubMed | Voir la publication source Monoclonal antibody (mAb)-based therapies have revolutionized cancer treatment; however, their clinical efficacy is oft… | Cancer immunology research 2026-11-15 04:37:24 | Source |
| Precision Fc remodeling via glycosylation-competent CHO display enabl… Tafasitamab and NK cells · PMID 41923108 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source BACKGROUND: Improving tumor cell clearance by therapeutic antibodies remains a translational bottleneck because wild-ty… | Journal of biological engineering 2026-11-15 04:37:24 | Source |
| The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural kil… Tafasitamab and NK cells · PMID 23277329 | Lupus | À vérifier | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | Leukemia 2026-11-15 04:37:24 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||